Alzheimer’s disease has emerged as the major health challenge of our generation. Against the backdrop of an aging population, brought about by meaningful advances in care for heart disease and cancer, Alzheimer’s disease affects over 5 million Americans and is the only top cause of death with no therapy to stop or slow it. Biotechnology is the most promising weapon against this epidemic. We will discuss what we have learned from past clinical trials, and what to expect in the near future.
Geoffrey A. Kerchner, MD, PhD, is Senior Medical Director at Genentech, Inc., and Adjunct Clinical Associate Professor of Neurology and Neurological Sciences at Stanford University School of Medicine. Geoffrey designs and oversees clinical trials of novel therapies for Alzheimer’s disease and other neurodegenerative illnesses, while also maintaining an active clinical practice at an academic memory clinic. He is also on the Board of Directors of the Alzheimer’s Association of Northern California and Northern Nevada. Geoffrey graduated from Harvard College and received his MD and PhD degrees from Washington University in St. Louis.
Introduction by VP, Andrew Dahlkemper.
source